###begin article-title 0
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 74 78 <span type="species:ncbi:10090">Mice</span>
CD133+ Anaplastic Thyroid Cancer Cells Initiate Tumors in Immunodeficient Mice and Are Regulated by Thyrotropin
###end article-title 0
###begin p 1
Conceived and designed the experiments: RYL. Performed the experiments: SF ML AS DT. Analyzed the data: SF ML AS DT. Wrote the paper: RYL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 58 63 <span type="species:ncbi:9606">human</span>
Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies. Its rapid onset and resistance to conventional therapeutics contribute to a mean survival of six months after diagnosis and make the identification of thyroid-cancer-initiating cells increasingly important.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 151 159 151 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 203 204 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 310 317 310 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 382 383 382 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 486 487 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 577 583 577 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 593 598 593 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 693 699 693 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 933 934 933 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1005 1009 1005 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 1014 1018 1014 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct4</italic>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 1111 1119 <span type="species:ncbi:9606">patients</span>
In prior studies of ATC cell lines, CD133+ cells exhibited stem-cell-like features such as high proliferation, self-renewal and colony-forming ability in vitro. Here we show that transplantation of CD133+ cells, but not CD133- cells, into immunodeficient NOD/SCID mice is sufficient to induce growth of tumors in vivo. We also describe how the proportion of ATC cells that are CD133+ increases dramatically over three months of culture, from 7% to more than 80% of the total. This CD133+ cell pool can be further separated by flow cytometry into two distinct populations: CD133+/high and CD133+/low. Although both subsets are capable of long-term tumorigenesis, the rapidly proliferating CD133+/high cells are by far the most efficient. They also express high levels of the stem cell antigen Oct4 and the receptor for thyroid stimulating hormone, TSHR. Treating ATC cells with TSH causes a three-fold increase in the numbers of CD133+ cells and elicits a dose-dependent up-regulation of the expression of TSHR and Oct4 in these cells. More importantly, immunohistochemical analysis of tissue specimens from ATC patients indicates that CD133 is highly expressed on tumor cells but not on neighboring normal thyroid cells.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 244 245 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
To our knowledge, this is the first report indicating that CD133+ ATC cells are solely responsible for tumor growth in immunodeficient mice. Our data also give a unique insight into the regulation of CD133 by TSH. These highly tumorigenic CD133+ cells and the activated TSH signaling pathway may be useful targets for future ATC therapies.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 59 62 59 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Cancer1">[1]</xref>
###xml 179 182 179 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Davies1">[2]</xref>
###xml 239 242 239 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Cancer1">[1]</xref>
###xml 900 903 900 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Pierie1">[3]</xref>
###xml 1158 1161 1158 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Reya1">[4]</xref>
###xml 1163 1166 1163 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Hope1">[5]</xref>
###xml 1743 1744 1743 1744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1748 1749 1748 1749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1754 1755 1754 1755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1757 1760 1757 1760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Hope1">[5]</xref>
###xml 1785 1786 1785 1786 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1790 1793 1790 1793 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 1795 1798 1795 1798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-AlHajj1">[6]</xref>
###xml 1819 1820 1819 1820 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1822 1825 1822 1825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Singh1">[7]</xref>
###xml 1859 1860 1859 1860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1862 1865 1862 1865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-RicciVitiani1">[8]</xref>
###xml 1866 1870 1866 1870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Dou1">[11]</xref>
###xml 162 168 <span type="species:ncbi:9606">people</span>
###xml 233 238 <span type="species:ncbi:9606">women</span>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
Thyroid cancer is the most common type of endocrine cancer [1]. Its incidence is increasing more rapidly than any other solid tumor - about 3 percent per 100,000 people each year [2] - and it is now the seventh most common cancer in women [1]. More than 90% of thyroid cancers are derived from thyroid follicular cells, are well differentiated and have a favorable prognosis. In contrast, anaplastic thyroid cancer (ATC), an undifferentiated thyroid cancer, is significantly more severe than other thyroid cancers and has a poor prognosis. Ninety percent of patients with ATC die within six months. Although ATC accounts for more than 50% of deaths associated with thyroid cancer every year, the causes of this disease are largely unknown. Current treatments for ATC are aggressive - including surgery, radiation therapy and chemotherapy - but no study has shown a convincing improvement in survival [3], perhaps because they do not adequately target the cancer-initiating cells. Most cancer therapies target differentiated or differentiating cells, regardless of whether or not they are cancerous. However, if the disease is due to cancer stem cells (CSCs) [4], [5], this could be the wrong approach. Like normal stem cells, CSCs can both self-renew and produce differentiated progeny, including a phenotypically diverse tumor cell population to drive tumorigenesis. Several lines of evidence suggest that CSCs, which are highly resistant to standard chemotherapeutic agents and radiation, sustain the disease in late phases of malignancy. To date, CSCs have been isolated based on their ability to express specific cell surface molecules in hematologic malignancies and epithelial-cell-derived cancers, including acute myeloid leukemia (CD34+CD38-CD123+) [5], mammary carcinoma (CD44+CD24low) [6], brain tumors (CD133+) [7], colon cancer and melanoma (CD133+) [8]-[11].
###end p 9
###begin p 10
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Yin1">[12]</xref>
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Yin2">[15]</xref>
###xml 508 512 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Yin2">[15]</xref>
###xml 513 517 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Ferrandina1">[24]</xref>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 647 648 647 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 814 822 814 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 822 826 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Zito1">[25]</xref>
###xml 563 568 <span type="species:ncbi:9606">human</span>
CD133 (prominin-1) is a five-transmembrane domain glycoprotein specifically expressed on populations of hematopoietic stem and progenitor cells from fetal and adult cord blood, peripheral blood and bone marrow [12]-[15]. Although its biological function remains unknown, it also serves as a marker of stem cells in a variety of non-hematopoietic tissues, including neural and glial cells in the fetal brain as well as prostatic epithelia, muscle, kidney, liver and corneal stroma, and some cancerous tissues [15]-[24]. Recently, Zito et al reported that, of four human ATC cell lines examined, two - ARO and KAT-4 - contain subpopulations of CD133+ cells that exhibit stem cell-like features such as rapid proliferation, an ability to self-renew and form colonies, and resistance to chemotherapy-induced apoptosis in vitro[25]. As a result, these populations are believed to be able to initiate tumor growth, although this hypothesis has not yet been validated in animal models.
###end p 10
###begin p 11
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 78 85 78 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 164 165 164 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 206 212 206 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 222 227 222 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 266 272 266 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 279 284 279 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 752 758 752 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 768 773 768 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 878 884 878 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 1082 1083 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1289 1290 1289 1290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
Here we evaluate the tumorigenic potentials of ATC-derived CD133+ populations in vivo. We used fluorescent-activated cell sorting (FACS) to further divide the CD133+ cells into two distinct fractions: CD133+/high and CD133+/low. We then compared the ability of CD133+/high, CD133+/low and CD133- cells to engraft and give rise to subcutaneous tumors in NOD/SCID mice. We used two xenotransplantation models in our study to explore the possible existence of CSCs in ATC: limiting dilution transplantation experiments to determine whether our xenograft system was qualitative and capable of detecting single tumor-initiating cells, and a serial xenograft model to test the cells' self-renewal and lineage capacities. We observed that, although both CD133+/high and CD133+/low cells generate subcutaneous xenograft tumors that display histology resembling the primary tumors, CD133+/high cells initiate earlier and more aggressive tumor growth. We also found that thyroid-stimulating hormone (TSH), the main regulator of thyroid gland function, is important for the growth of the CD133+ population. Unlike normal thyroid cells, ATC tissue specimens were clearly positive for CD133. Our findings, together with the identification of thyroid CSCs and the elucidation of the role of TSH in CD133+ cell growth, may lead to new diagnostic markers and therapies to treat this devastating disease.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 22 27 <span type="species:ncbi:9606">human</span>
CD133 is expressed on human ATC cell lines but not on papillary thyroid cancer cell lines
###end title 13
###begin p 14
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 293 294 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 393 400 393 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g001">Fig. 1A</xref>
###xml 580 581 580 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 595 596 595 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 604 611 604 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g001">Fig. 1B</xref>
###xml 695 696 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 850 851 850 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 976 982 976 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g001">Fig 1B</xref>
###xml 96 101 <span type="species:ncbi:9606">human</span>
To determine whether a CSC population exists in ATC, we examined CD133 expression in a panel of human thyroid cancer cell lines. Flow cytometric analysis revealed that CD133 is expressed in two ATC cell lines, ARO (in which 7.02% of cells are CD133+) and FRO (in which 6.32% of cells are CD133+), but not in either of two well-differentiated papillary thyroid cancer cell lines (NPA and TPC) (Fig. 1A). These results suggest that CD133 expression is uniquely associated with undifferentiated ATC. Immunofluorescent staining confirms the expression of CD133 on the surface of CD133+ but not CD133- cells (Fig. 1B). Moreover, the two CD133 populations grow differently in culture. In tumors, CD133+ cells exhibit pleomorphic giant cell nuclei and appear granular and dense; in two-dimensional cultures they form tight round colonies. In contrast, CD133- cells are devoid of most of these features. Similar to ARO cells, they grow independently as small, round cells in culture (Fig 1B).
###end p 14
###begin title 15
###xml 7 8 7 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 50 55 <span type="species:ncbi:9606">human</span>
A CD133+ population of cancer cells is present in human ATC cell lines.
###end title 15
###begin p 16
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 261 262 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 418 430 418 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">green signal</italic>
###xml 470 471 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
(A) Flow cytometric analysis of CD133 expression in ARO, FRO, NPA and TPC cell lines. Black lines represent positive staining for CD133, grey shows isotype controls. (B) Sorted CD133+ cells form tight round colonies in two-dimensional cell cultures, while CD133- cells grow independently as small round cells. Immunofluorescent images of CD133+ cells (upper middle panel; 63x magnification) show CD133 expression as a green signal at the cell surface. In contrast, CD133- cells lack this signal (lower middle panel; 20x magnification).
###end p 16
###begin title 17
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD133+ cells express high levels of the genes for Oct4 and TSHR
###end title 17
###begin p 18
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 129 134 129 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct-4</italic>
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 155 162 155 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g002">Fig. 2A</xref>
###xml 192 198 188 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 228 229 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 431 432 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 489 493 481 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Zito1">[25]</xref>
###xml 571 572 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 589 590 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 656 660 648 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 680 681 672 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 694 701 686 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g002">Fig. 2A</xref>
###xml 731 737 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 767 768 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 939 940 923 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1042 1043 1026 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis indicated that CD133+ cells express about four times as much Oct-4 as do CD133- cells (Fig. 2A; 1.02+/-0.25 (mean+/-s.e.m.) versus 0.27+/-0.10 (mean+/-s.e.m.), P<0.05). Oct4 is a member of the POU family of transcription factors and plays a key role in the maintenance of pluripotency and the proliferation of embryonic stem cells. The expression of Oct4 in CD133+ cells indicates that, consistent with a previous report [25], this population has stem-cell-like properties that are not shared with CD133- cells. The CD133+ population also expresses approximately 13-fold higher levels of TSHR than does the CD133- population (Fig. 2A; 1.05+/-0.53 (mean+/-s.e.m.) versus 0.08+/-0.03 (mean+/-s.e.m.), P<0.01). TSHR is a G protein-coupled glycoprotein receptor that stimulates the growth of normal and cancerous thyroid cells in the presence of TSH. Our discovery that CD133+ cells express significantly higher levels of TSHR implies that TSH also regulates the growth of CD133+ cells.
###end p 18
###begin title 19
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct4</italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
CD133+ cells express high levels of Oct4 and TSHR genes.
###end title 19
###begin p 20
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct-4</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 181 182 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct4</italic>
###xml 274 275 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct4</italic>
###xml 439 440 439 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 295 300 <span type="species:ncbi:9606">human</span>
(A) qRT-PCR analysis indicates that CD133+ cells express higher levels of Oct-4 and TSHR than do CD133- cells. Results are shown as mean and s.e.m. Asterisk: P<0.05; two asterisks: P<0.01. (B) TSH upregulates the expression of TSHR and Oct4 and increases the number of CD133+ cells. Left panel: human recombinant TSH elicits a dose-dependent upregulation of TSHR and Oct4 mRNA levels in unsorted ARO cells. Right panel: the number of CD133+ cells increases three-fold in response to TSH stimulation.
###end p 20
###begin title 21
Enhanced cell proliferation and up-regulation of Oct4 and TSHR genes in response to TSH signaling
###end title 21
###begin p 22
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-DeVita1">[26]</xref>
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Yano1">[30]</xref>
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 312 313 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 478 482 474 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 487 491 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct4</italic>
###xml 499 506 495 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g002">Fig. 2B</xref>
###xml 612 619 608 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g002">Fig. 2B</xref>
###xml 710 711 706 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 724 732 720 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 380 385 <span type="species:ncbi:9606">human</span>
Clinical studies have indicated that elevated TSH levels may be a marker for the development of thyroid cancer [26]-[30]. In particular, most thyroid cancer patients have above-normal TSH levels. Because CD133+ cells express much higher levels of TSHR than do CD133- cells, we examined the effect of TSH on CD133+ populations. ARO cells cultured with 0-1000 microU/ml recombinant human TSH for 48 hours exhibited a dose-dependent increase in the relative expression of both the TSHR and Oct4 genes (Fig. 2B). The number of ARO cells expressing CD133 also increased about three-fold in response to TSH treatment (Fig. 2B). Together, these observations demonstrate that TSH induces the proliferation of the CD133+ populations in vitro.
###end p 22
###begin title 23
###xml 23 28 <span type="species:ncbi:9606">human</span>
ARO cells reconstitute human ATC tumors in vivo
###end title 23
###begin p 24
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 417 424 417 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g003">Fig. 3A</xref>
###xml 685 692 685 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g003">Fig. 3A</xref>
###xml 812 813 812 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 847 848 847 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 994 995 982 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1070 1077 1046 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g003">Fig. 3B</xref>
###xml 1340 1341 1316 1317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1439 1446 1415 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g001">Fig. 1A</xref>
###xml 1531 1537 1507 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g004">Fig. 4</xref>
###xml 1620 1621 1596 1597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1653 1654 1629 1630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:10090">Mice</span>
###xml 327 332 <span type="species:ncbi:9606">human</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
###xml 1125 1130 <span type="species:ncbi:9606">human</span>
###xml 1209 1213 <span type="species:ncbi:10090">mice</span>
To develop a reliable model of human ATC biology, we established four ARO subcutaneous xenografts in eight-week-old female NOD/SCID mice. Mice injected with single-cell suspensions of 106 ARO cells developed palpable tumors within a few days and visible tumors within 21 days. These tumors are remarkably similar to those from human patients and exhibit little resemblance to the original thyroid follicle structure (Fig. 3A). Importantly, we found that the tumorigenic potential of the ARO cells varies with their passage number: cells that had been cultured longer formed larger and more aggressive tumors when transplanted into NOD/SCID mice than did cells of lower passage number (Fig. 3A). We speculate that this phenomenon is due to the positive selection over time of the more robustly proliferating CD133+ cells at the expense of the CD133- cells. Indeed, we found that two ARO cultures that had been passaged 50 or more times contained a higher proportion (approximately50.1%) of CD133+ cells than did ARO cultures of lower passage numbers (approximately21.9%)(Fig. 3B). Together, these results demonstrate that the human ARO cell line contains cells with the capacity to form new tumors in NOD/SCID mice and that CD133 expression levels are positively correlated with tumor formation. Furthermore, the rapid proliferation of CD133+ cells results in the robust positive selection of these cells over time-from the original 7.02% (Fig. 1A) of the total population to more than 80% after three months of continuous culture (Fig. 4). These results demonstrate that an extended period of culture can transform CD133--dominant populations into CD133+-dominant populations.
###end p 24
###begin title 25
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
ARO cells reconstitute human ATC tumors in NOD/SCID mice and high-passage ARO cells generate faster-growing, larger tumors in NOD/SCID mice than do low-passage ARO cells.
###end title 25
###begin p 26
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 533 534 533 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 184 189 <span type="species:ncbi:9606">human</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
(A) All mice injected with 106 ARO cells developed tumors within 21 days. Hematoxylin-eosin analysis of these xenografts showed that they are remarkably similar to tumor sections from human patients. Note that tumors generated from high-passage ARO cells formed larger and more aggressive tumors when subcutaneously transplanted into NOD/SCID mice than did tumors generated from low-passage ARO cells. (B) FACS analysis show that ARO cells of high passage number (right panel, passage number>50) contain a greater proportion of CD133+ cells than do ARO cells of low passage number (left panel, passage number<10).
###end p 26
###begin title 27
###xml 5 11 5 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OCT4</italic>
###xml 85 90 85 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
CD133+/high subpopulations express higher levels of TSHR and OCT4 genes than do CD133+/low and CD133- subpopulations.
###end title 27
###begin p 28
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 61 67 61 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 76 81 76 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 266 272 266 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 282 287 282 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 329 330 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 452 453 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
(A) The CD133+ population can be further separated into CD133+/high and CD33+/low populations by FACS. (B) The purity of each sorted fraction was confirmed by FACS analysis. (C) ARO cell proliferation assay (left panel). Cell proliferation assays indicate that CD133+/high and CD133+/low cells proliferate more rapidly than CD133- cells at culture days four and eight (right panel). (D) qRT-PCR analysis. Results are shown as mean and s.e.m. Asterisk, P<0.05.
###end p 28
###begin title 29
###xml 5 11 5 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 76 81 76 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 91 92 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
CD133+/high cells express higher levels of TSHR and Oct4 genes than do CD133+/low and CD133- cells
###end title 29
###begin p 30
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 93 99 93 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 109 114 109 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 116 123 116 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g004">Fig. 4A</xref>
###xml 202 207 202 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 223 229 223 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 251 258 251 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g004">Fig. 4A</xref>
###xml 317 324 317 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g004">Fig. 4B</xref>
###xml 487 493 487 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 503 508 503 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 563 564 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 579 587 579 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 589 596 589 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g004">Fig. 4C</xref>
###xml 647 653 647 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 700 704 700 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct4</italic>
###xml 709 713 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 726 727 726 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 776 783 776 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g004">Fig. 4D</xref>
###xml 821 826 821 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCR4</italic>
###xml 956 960 956 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-DeFalco1">[31]</xref>
###xml 962 966 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Hwang1">[32]</xref>
###xml 1015 1020 1015 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCR4</italic>
###xml 1045 1050 1045 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxa2</italic>
###xml 1106 1113 1106 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g004">Fig. 4D</xref>
The CD133+ cell pool can be further separated by FACS into two distinct subpopulations: CD133+/high and CD133+/low (Fig. 4A). In a highly passaged culture of ARO cells, about 80% of the cells were CD133+/low, 16% were CD133+/high, and 4% were CD133- (Fig. 4A). We confirmed the purity of the fractions after sorting (Fig. 4B) and conducted cell proliferation assays to determine whether there are any differences in the proliferation rates of these subpopulations. As expected, the CD133+/high and CD133+/low subpopulations proliferate more rapidly than the CD133- subpopulation in vitro (Fig. 4C). qRT-PCR analysis further revealed that the CD133+/high subpopulation expresses the highest levels of Oct4 and TSHR, while CD133- cells express the lowest levels of these genes (Fig. 4D). We also assessed the expression of CXCR4, the receptor for the stromal cell-derived factor-1 CXCL2 chemokine that is expressed in a variety of solid tumors including ATC [31], [32]. We found that the expression levels of neither CXCR4 nor the endoderm marker Foxa2 differed significantly among the three subpopulations (Fig. 4D).
###end p 30
###begin title 31
###xml 5 11 5 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
CD133+/high cells are highly tumorigenic in vivo
###end title 31
###begin p 32
###xml 197 203 197 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 210 215 210 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 408 415 384 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005395-t001">Table 1</xref>
###xml 453 459 429 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 571 577 547 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 651 656 627 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 772 777 748 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 853 858 829 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 931 932 907 908 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1004 1010 980 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 1090 1095 1066 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 1135 1141 1111 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 1164 1165 1140 1141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1199 1200 1175 1176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1263 1268 1239 1244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 1309 1310 1285 1286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1348 1349 1324 1325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1427 1433 1403 1409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 1443 1448 1419 1424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 1481 1487 1457 1463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 1565 1570 1541 1546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
###xml 715 719 <span type="species:ncbi:10090">mice</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
###xml 893 897 <span type="species:ncbi:10090">mice</span>
###xml 1051 1055 <span type="species:ncbi:10090">mice</span>
###xml 1103 1107 <span type="species:ncbi:10090">mice</span>
###xml 1231 1235 <span type="species:ncbi:10090">mice</span>
To test our hypothesis that only a small subpopulation of highly proliferative ARO cells is responsible for tumor formation, we transplanted groups of NOD/SCID mice with increasing numbers of CD133+/high, CD133+/low and CD133- cells - from an amount normally unable to initiate tumor growth (approximately1,000 cells) to an amount that always initiates tumor growth (approximately100,000 cells). As shown in Table 1, injection of 100,000 to 10,000 CD133+/high cells gave rise to visible tumors in all mice (4/4) within four weeks and 1 of 2 mice injected with 1,000 CD133+/high cells developed a tumor. In contrast, although injection of 100,000 CD133+/low cells also gave rise to new tumors (4/4), only 1 out of 4 mice developed a tumor after an injection of 10,000 CD133+/low cells, and no tumors were observed when mice were injected with 1,000 CD133+/low cells. No tumors were observed in mice injected with any number of CD133- cells. Notably, subcutaneous tumors derived from the injection of CD133+/high ARO cells grew more quickly in NOD/SCID mice than did tumors derived from CD133+/low cells: mice injected with 100,000 CD133+/high cells developed 250 mm3 tumors within 16 days and 1000 mm3 tumors within 35 days whereas mice injected with 100,000 CD133+/low cells required 35 days to develop 250 mm3 tumors and 45 days to develop 1000 mm3 tumors (data not shown). These observations suggest that, although both CD133+/high and CD133+/low cells can initiate tumors, CD133+/high cells initiate tumor growth more efficiently and grow more quickly than CD133+/low cells.
###end p 32
###begin title 33
###xml 46 51 <span type="species:ncbi:9606">human</span>
Limiting-dilution transplantation analysis of human ARO cells.
###end title 33
###begin title 34
###xml 40 46 40 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 55 60 55 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Long-term tumorigenic potential of CD133+/high and CD33+/low cells in NOD/SCID mice
###end title 34
###begin p 35
###xml 65 71 65 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 81 86 81 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 354 360 354 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 370 375 370 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 417 423 417 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 433 438 433 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 542 548 542 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g005">Fig. 5</xref>
###xml 635 642 635 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 791 797 791 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 883 889 883 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 899 904 899 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 1051 1058 1051 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
Cells from primary tumors originating from the injection of CD133+/high and CD133+/low cells were serially transplanted into NOD/SCID mice to determine the long-term tumorigenic potential of the cells. The limiting-dilution transplantation experiments described above indicate that the size of the tumors is positively correlated with the number of CD133+/high and CD133+/low cells injected. Tumors derived from CD133+/high and CD133+/low primary and secondary xenografts consistently reproduced the primary tumors at the histological level (Fig. 5). Although both subpopulations not only maintained their tumorigenic potential during in vivo passaging but also increased their aggressiveness, as indicated by the faster growth and increasing size of successively generated tumors, the CD133+/high cells are overall more aggressive. Together these results suggest not only that CD133+/high and CD133+/low cells have long-term tumorigenic potential, but also that our xenograft model system quantitatively and qualitatively recapitulates tumorigenesis in vivo.
###end p 35
###begin title 36
###xml 40 46 40 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 56 61 56 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
Long-term tumorigenic potential of CD133+/high and CD133+/low cells.
###end title 36
###begin p 37
###xml 9 15 9 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 25 30 25 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 176 182 176 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 192 197 192 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 266 271 <span type="species:ncbi:10090">mouse</span>
(A) CD133+/high and CD133+/low subsets of ARO cells each exhibit long-term tumorigenic potential. Subcutaneous tumors in NOD/SCID mice derived from secondary injection of CD133+/high and CD133+/low cells. (B) Hematoxylin-eosin (H&E) and CD133 expression analysis of mouse xenografts generated from primary and secondary xenografts.
###end p 37
###begin title 38
###xml 49 54 <span type="species:ncbi:9606">human</span>
CD133 is highly expressed in surgical samples of human ATC but not in normal thyroid cells
###end title 38
###begin p 39
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 564 570 564 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g006">Fig. 6</xref>
###xml 684 690 684 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g006">Fig. 6</xref>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 359 366 <span type="species:ncbi:9606">patient</span>
To understand the role of CD133 in human ATC, it is necessary to verify whether the CD133 protein is expressed in surgical samples derived from patients with pathological and clinical diagnoses of ATC. We used immunohistochemical staining to evaluate levels of CD133 expression in a set of archival, routinely processed, formalin-fixed, paraffin-embedded ATC patient tissue specimens (n = 10). We detected CD133 expression in 8 out of 10 (80%) ATC specimens. Staining intensity ranged from strong to moderate. Representative pictures of ATC specimens are shown in Fig. 6. Strikingly, CD133 is strongly expressed on tumor cells, but not on neighboring normal thyroid follicular cells (Fig. 6). Antibody specificity was demonstrated through peptide blocking. Together these data indicate that CD133 is overexpressed in ATC clinical samples with respect to normal thyroid tissues.
###end p 39
###begin title 40
###xml 49 54 <span type="species:ncbi:9606">human</span>
CD133 is highly expressed in surgical samples of human ATC but not in normal thyroid cells.
###end title 40
###begin p 41
(A-D) Immunohistochemical analysis of CD133 expression in ATC specimens. Positive cells are brown. Note that normal thyroid cells do not express CD133 (arrow). The photo on the right bottom is CD133 antibody plus peptide competition staining.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 549 555 549 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 578 583 578 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 661 662 661 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1022 1029 1022 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1104 1108 1104 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Lin1">[33]</xref>
###xml 1110 1114 1110 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Thomas1">[34]</xref>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 477 482 <span type="species:ncbi:9606">human</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
ATC is one of the most lethal of all human neoplasms. It is highly resistant to conventional therapies and its mortality rate approaches 100%. The relative rarity and rapidly fatal nature of ATC complicate both its diagnosis and treatment. The present study demonstrates for the first time that only a subpopulation of ATC cells is able to form tumors in NOD/SCID mice. We identified and isolated these cells based on the expression of a cell surface CSC marker, CD133, in the human ATC cell line ARO. Our data demonstrate that as few as 1,000 CD133+/high cells and 10,000 CD133+/low cells can form tumors in NOD/SCID mice. In contrast, mice injected with CD133- cells remained tumor free throughout the study period. These data reveal that tumorigenic and non-tumorigenic cells co-exist within ATC, and imply that not all tumor cells are able to initiate neoplastic growth. Rather, anaplastic tumors are generated by a small subset of CSC cells that can self-renew and differentiate into the entire tumor population. Our in vivo data support a previously uncharacterized CSC model for ATC tumorigenesis [33], [34].
###end p 43
###begin p 44
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 201 205 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Zito1">[25]</xref>
###xml 279 280 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 282 289 282 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g001">Fig. 1A</xref>
###xml 361 368 361 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g001">Fig. 1B</xref>
###xml 551 555 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Zito1">[25]</xref>
###xml 796 802 796 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 844 845 844 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 853 859 853 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g003">Fig. 3</xref>
###xml 951 952 951 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1166 1171 1166 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1330 1334 1330 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Schweppe1">[35]</xref>
###xml 1397 1402 1397 1402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 1593 1598 <span type="species:ncbi:9606">human</span>
The current approach relies on two well-characterized human ATC cell lines: ARO and FRO. Zito et al previously reported that over 60% of ARO cells were CD133+, and that FRO cells did not express CD133 [25]. In contrast, we found that about 7% of both ARO and FRO cells were CD133+ (Fig. 1A). Furthermore, despite the fact that immunofluorescent staining by us (Fig. 1B) and others clearly show that CD133 is a cell surface protein, Zito's group described CD133 immunostaining as cytoplasmic and apical - atypical for a five-transmembrane glycoprotein [25]. There are several possible explanations for these discrepancies. First, because the sources of cell lines are different, it is possible that they inherited different characteristics. For example, we describe here how, like many CSCs, CD133+/high cells proliferate more rapidly than CD133- cells (Fig. 3). Over an extended period of continuous culturing, we observed that the proportion of CD133+ cells in the ARO culture increased dramatically from 7% to 80%. If Zito's group studied early-passage FRO cells they may have mistakenly concluded that the cells did not express CD133. A recent report by Schweppe et al also suggests that the purported ATC cell lines ARO and KAT-4 are actually derived from the colon cancer cell line HT-29 and are not of thyroid cancer origin [35]. Although it is not clear whether the cell lines used by Zito et al were contaminated, genetic analysis and DNA fingerprinting studies should be used to clarify the identity of these cell lines. Finally, it will be necessary to confirm our findings in fresh human ATC surgical tissue samples because cell lines do not always recapitulate all aspects of primary tumors. However, the rarity of the disease may make this difficult to achieve.
###end p 44
###begin p 45
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 745 746 745 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 830 831 830 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 945 953 <span type="species:ncbi:9606">patients</span>
The rapid proliferation of CD133+ cells may at least partially explain ATC's fatal nature. Existing diagnostic methods are based upon several characteristics: a lack of radioactive iodine uptake, a direct extension into soft tissues, and a rapidly enlarging neck mass (mean size at presentation: 8 cm). Most patients are struggling with breathing problems by the time they are diagnosed, and most of these cancers are already stage IV-they have spread extensively to cervical lymph nodes and distant organs such as lung and bone, and are difficult to target and kill even with surgery. Because it is likely that the fast-growing nature of ATC and the subsequent high casualties are due to the highly proliferative and tumorigenic nature of CD133+ cells, it seems reasonable that future therapies should be designed to target CD133+ populations. Drug therapies targeting these populations are likely to differ from current chemotherapies for ATC patients and may be more successful in treating the disease.
###end p 45
###begin p 46
###xml 200 206 200 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 216 221 216 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 347 353 347 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g005">Fig. 5</xref>
###xml 397 398 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 840 841 840 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 878 879 878 879 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Our immunohistochemical studies of clinical ATC specimens clearly showed that CD133 is expressed on tumor cells but not on neighboring normal thyroid cells. More importantly, tumors derived from CD133+/high and CD133+/low primary and secondary xenografts faithfully reproduced the primary tumors at the histological level in our xenograft models (Fig. 5). Together these results suggest that CD133+ cells maintain their tumorigenic potential during in vivo passaging and are indeed CSCs. CSCs self-renew and reconstitute their particular organ systems through a process of asymmetrical division that generates one new stem cell and one daughter cell capable of differentiation. They can also divide symmetrically to form either two normal daughter cells or two stem cells, depending on surrounding extracellular factors. Our data that CD133+ cells generate new tumorigenic CD133+ cells in addition to mixed populations of non-tumorigenic cells further support the notion that they are true CSCs.
###end p 46
###begin p 47
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 240 244 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Shmelkov1">[36]</xref>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 308 309 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 383 384 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 433 434 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 474 478 474 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Shmelkov1">[36]</xref>
###xml 670 676 670 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 686 691 686 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 753 759 753 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 808 813 808 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 1700 1704 1700 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Ahn1">[37]</xref>
###xml 95 110 <span type="species:ncbi:10090">transgenic mice</span>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 738 742 <span type="species:ncbi:10090">mice</span>
###xml 1004 1008 <span type="species:ncbi:10090">mice</span>
Shmelkov et al recently reported that CD133 may not be a reliable marker for colon CSCs. Using transgenic mice expressing LacZ under the CD133 promoter, they found that CD133 was broadly expressed in normal and cancerous colonic epithelium [36]. Furthermore, they reported that although both CD133+ and CD133- metastatic colon cancer cells can initiate tumors in NOD/SCID mice, CD133+ cells can give rise to the more aggressive CD133- cells during the metastatic transition [36]. ATC is an undifferentiated thyroid cancer, and its behavior is largely different from colon cancer. For example, we found that normal thyroid cells do not express CD133. Moreover, both CD133+/high and CD133+/low subsets can initiate tumor growth in NOD/SCID mice, but CD133+/high cells generate more aggressive tumors than CD133+/low cells. It is not clear in our study which CD133 subsets play a role in ATC metastases. Our current xenograft model depends upon the subcutaneous transplantation of CD133 cells into NOD/SCID mice. This location is not a normal niche of thyroid cancer cells and may not faithfully recapitulate the environment experienced by the cancer cells in the original tumor. Although we have shown that tumors derived from either bulk or sorted ARO cell populations are remarkably similar to the primary tumor, it is conceivable that the thyroid bed may better support the growth and differentiation of thyroid CSCs. This point is even more important when we consider that ATC is a locally aggressive type of thyroid tumor with high rate of distant metastases. Therefore, it is critically important to establish an orthotopic model in which tumor cells are injected directly into the thyroid gland [37].
###end p 47
###begin p 48
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 732 737 732 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 762 763 762 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 905 909 905 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Zito1">[25]</xref>
###xml 1550 1551 1550 1551 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1718 1719 1718 1719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1861 1867 1861 1867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005395-g007">Fig. 7</xref>
###xml 1951 1952 1951 1952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2113 2114 2113 2114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1653 1661 <span type="species:ncbi:9606">patients</span>
We found that CD133+ cells preferentially overexpress genes, such as Oct4, that are normally enriched in embryonic stem cells. Our previous RT-PCR gene expression profiles indicate that ATC cell lines express the embryonic stem cell markers Rex1, Oct4 and Nanog. The expression of a number of endodermal markers, including Sox17, Foxa2 and Sox 7, is also detected (data not shown). Although these cancer cell lines also express TSHR and the thyroid transcription factor Pax8, other markers of terminally differentiated thyroid cells, such as the sodium-iodide symporter and thyroglobulin, are not expressed in these cell lines (Friedman and Lin, unpublished observations). These results are in agreement with those reported by Zito et al who found that ARO/CD133+ cells express the thyroblast-specific transcription factor TTF-1 and Oct4, but not thyroglobulin, thyroperoxidase or sodium-iodine symporter [25]. Together these findings indicate that ATC cells have not only begun to proliferate uncontrollably, a property common to all cancer cells, but also that they are losing characteristics of differentiated thyroid cells. Our results reveal a previously unknown link between genes associated with embryonic stem cells and thyroid cells and support the possibility that these genes contribute to the CSC-like phenotypes exhibited by many tumors. These observations suggest that the regulatory networks controlling the function of thyroid cells may also be active in ATCs. Our discovery that TSH can regulate the proliferation and growth of CD133+ cells may have important implications. Clinically, the highest incidence of thyroid cancer occurs in patients with abnormally elevated TSH levels. We found that CD133+ cells overexpress the TSHR gene. Furthermore, this expression is positively regulated by TSH, implying an autoregulatory feedback mechanism (Fig. 7). It is important to further investigate how TSH affects the proliferation of CD133+ cells and, by extension, that of other CSCs. The role of Oct4 activation in cancer survival and the genes and proteins that facilitate the self-renewal of CD133+ also warrant investigation.
###end p 48
###begin title 49
Model depicting the role of TSH signaling in ATC development.
###end title 49
###begin p 50
###xml 103 109 103 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 135 140 135 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
TSH, thyroid stimulating hormone, TSHR, the receptor for thyroid stimulating hormone, Red circle, CD133+/high cells, blue circle, CD133+/low cells, yellow circle, CD133- cells.
###end p 50
###begin p 51
###xml 149 150 149 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
In summary, our identification of these tumorigenic ATC cells is a critical first step in understanding how TSH signaling affects the growth of CD133+ cells and in developing more effective therapies for ATC. The diagnosis of ATC currently relies on a complex panel of pathological parameters and the use of CD133 as a novel marker to identify ATC-cancer-initiating cells may be a more reliable way to detect and monitor cancer progression. These findings should stimulate additional studies to determine whether quantitative or qualitative differences in CD133 expression in ATC have prognostic value. Furthermore, they suggest that CD133 may itself be a potential therapeutic target in this disease.
###end p 51
###begin title 52
Materials and Methods
###end title 52
###begin title 53
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human thyroid cancer cell culture
###end title 53
###begin p 54
###xml 546 547 546 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 897 901 891 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-vanStaveren1">[38]</xref>
###xml 902 906 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005395-Fiore1">[41]</xref>
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 112 117 <span type="species:ncbi:9606">human</span>
###xml 349 355 <span type="species:ncbi:9913">bovine</span>
###xml 776 781 <span type="species:ncbi:9606">human</span>
###xml 945 950 <span type="species:ncbi:9606">human</span>
Two undifferentiated human anaplastic thyroid carcinoma cell lines (ARO and FRO), and two poorly differentiated human papillary thyroid carcinoma cell lines (NPA and TPC), were obtained from Dr. James Fagin (Memorial Sloan-Kettering Cancer Center, New York). ARO, FRO and NPA cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS). The TPC cell line was cultured in Dulbecco's modified Eagle (DMEM, Gibco-BRL) high-glucose medium containing 10% FBS. Cultures were maintained in a humidified chamber in a 5% CO2/air mixture at 37degreesC. For each cell line, 15,000 to 30,000 cells were seeded in chamber slides and cultured until they reached confluence. Cells were harvested using standard methods. Karyotypes were determined for all the human thyroid cancer cell lines using GTG banding. The karyogram data were identical to the previously published reports [38]-[41] and confirmed these cell lines are of human origin.
###end p 54
###begin title 55
Flow cytometry
###end title 55
###begin p 56
Cells were dissociated with trypsin/EDTA for three minutes, and then washed and labeled with CD133/1(AC133)-APC antibody (Miltenyi Biotec) and sorted on a MoFlo Cell Sorter. Viability dye was used to eliminate dead cells. Side and forward scatter profiles were used to eliminate cell doublets. Cell purity was evaluated after sorting by FACS analysis. Flow cytometric analysis was performed on a FACS Calibur flow cytometer (BD Biosciences). FACS data were generated using FlowJo software (FlowJo LLC. Ashland, OR).
###end p 56
###begin title 57
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Subcutaneous transplantation of bulk and sorted cancer cells into NOD/SCID mice
###end title 57
###begin p 58
###xml 14 18 14 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</sup>
###xml 9 18 9 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prkdc<sup>scid</sup></italic>
###xml 259 265 259 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 272 277 272 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 287 288 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">Mice</span>
NOD.CB17-Prkdcscid/J (NOD/SCID) mice were obtained from the Jackson Laboratory and maintained under specific pathogen-free conditions with the approval of the Institutional Animal Care and Use Committee of Mount Sinai School of Medicine. Bulk and sorted CD133+/high, CD133+/low and CD133- cells were re-suspended in PBS/Matrigel and injected subcutaneously into NOD/SCID mice. Mice were sacrificed after four to eight weeks and the tumors were removed, fixed in 10% formalin and embedded in paraffin in preparation for immunohistochemistry. All animal experiments were performed according to approved institutional protocols.
###end p 58
###begin title 59
Alamar blue assay for cell proliferation
###end title 59
###begin p 60
###xml 21 27 21 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/high</sup>
###xml 34 39 34 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/low</sup>
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 198 199 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Bulk and sorted CD133+/high, CD133+/low and CD133- cells were seeded in triplicate into 96-well plates at a concentration of 104 cells/well in RPMI/5% FBS and placed in a humidified chamber of 5% CO2/air mixture at 37degreesC. For cell proliferation assays, Alamar Blue dye (Invitrogen) was added directly into culture media to a final concentration of 10%. After an additional hour of incubation, the plates were read in a fluorescent plate reader. As a negative control, Alamar blue was added to cell-free medium.
###end p 60
###begin title 61
Immunohistochemistry
###end title 61
###begin p 62
###xml 254 259 <span type="species:ncbi:9606">human</span>
Immunohistochemistry was performed on 10 archival routinely processed formalin-fixed, paraffin-embedded ATC tissue specimens. Paraffin sections were de-paraffined and then rehydrated with distilled water. The slides were subsequently incubated with anti-human CD133/1 (Abcam Inc.) antibody and visualized with Elite vector Stain ABC systems (Vector Laboratories) and DAB substrate (DakoCytomation) and counterstained with hematoxylin.
###end p 62
###begin title 63
qRT-PCR
###end title 63
###begin p 64
###xml 419 423 419 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 435 468 435 468 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCTGAGAATTGTGGTGTGGTTCGTTAG-3&#8242;</named-content>
###xml 470 474 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSHR</italic>
###xml 486 517 486 517 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGTTTGTAGTGGCTGGTGAGGAGAA-3&#8242;</named-content>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct4</italic>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>Oct4</italic></italic>
###xml 534 564 534 564 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATGCATTCAAACTGAGGTGCCTGC-3&#8242;</named-content>
###xml 523 565 523 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(forward), <named-content content-type="gene">5&#8242;-ATGCATTCAAACTGAGGTGCCTGC-3&#8242;</named-content>;</italic>
###xml 565 569 565 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oct4</italic>
###xml 581 611 581 611 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCACCCTTTGTGTTCCCAATTCCT-3&#8242;</named-content>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxa2</italic>
###xml 630 660 630 660 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCATTCCCAATCTTGACACGGTGA-3&#8242;</named-content>
###xml 662 667 662 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Foxa2</italic>
###xml 669 676 669 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">reverse</italic>
###xml 679 709 679 709 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCCTTGCAGCCAGAATACACATT-3&#8242;</named-content>
###xml 711 716 711 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCR4</italic>
###xml 728 758 728 758 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGGGAACTGAACATTCCAGAGCGT-3&#8242;</named-content>
###xml 760 765 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCR4</italic>
###xml 777 807 777 807 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AAACGTTCCACGGGAATGGAGAGA-3&#8242;</named-content>
###xml 809 814 809 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 826 852 826 852 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGCACCACCAACTGCTTAGC-3&#8242;</named-content>
###xml 854 859 854 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 871 898 871 898 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCATGGACTGTGGTCATGAG-3&#8242;</named-content>
###xml 298 303 <span type="species:ncbi:9606">Human</span>
Total RNA was isolated with the RNeasy kit (Qiagen) and treated with RNase-free DNase (Qiagen). Two micrograms of total RNA were reverse transcribed into cDNA using the Thermoscript First Strand Synthesis System (Invitrogen). Qiagen QuantiFast SYBR Green PCR kit was used for the qRT-PCR reaction. Human GAPDH was used as the housekeeping gene during the amplifications. The primers used in this study were as follows: TSHR (forward), 5'-CCTGAGAATTGTGGTGTGGTTCGTTAG-3'; TSHR (reverse), 5'-AGTTTGTAGTGGCTGGTGAGGAGAA-3'; Oct4(forward), 5'-ATGCATTCAAACTGAGGTGCCTGC-3';Oct4 (reverse), 5'-CCACCCTTTGTGTTCCCAATTCCT-3'; Foxa2 (forward), 5'-GCATTCCCAATCTTGACACGGTGA-3'; Foxa2 (reverse), 5'-GCCCTTGCAGCCAGAATACACATT-3'; CXCR4 (forward), 5'-AGGGAACTGAACATTCCAGAGCGT-3'; CXCR4 (reverse), 5'-AAACGTTCCACGGGAATGGAGAGA-3'; GAPDH (forward), 5'-TGCACCACCAACTGCTTAGC-3'; GAPDH (reverse), 5'-GGCATGGACTGTGGTCATGAG-3'.
###end p 64
###begin title 65
Statistical analysis
###end title 65
###begin p 66
###xml 156 157 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Statistical analysis was performed with Prism software. Numerical data are expressed as mean+/-s.e.m. Statistical differences are considered significant at P<0.05.
###end p 66
###begin p 67
###xml 75 80 <span type="species:ncbi:9606">human</span>
We thank Dr. James Fagin of Memorial Sloan-Kettering Cancer Center for the human thyroid cancer cell lines. We also thank Dr. Shu-Hsia Chen for advice with tumor xenotransplantation experiments. The immunohistochemistry was performed with the technical assistance of Shen Yao and Dr. David Burstein. We thank the Mount Sinai Flow Cytometry Shared Research Facility for sorting assistance.
###end p 67
###begin title 68
References
###end title 68
###begin article-title 69
Increasing incidence of thyroid cancer in the United States, 1973-2002.
###end article-title 69
###begin article-title 70
The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma.
###end article-title 70
###begin article-title 71
Stem cells, cancer, and cancer stem cells.
###end article-title 71
###begin article-title 72
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.
###end article-title 72
###begin article-title 73
Prospective identification of tumorigenic breast cancer cells.
###end article-title 73
###begin article-title 74
###xml 40 45 <span type="species:ncbi:9606">human</span>
Identification of a cancer stem cell in human brain tumors.
###end article-title 74
###begin article-title 75
###xml 32 37 <span type="species:ncbi:9606">human</span>
Identification and expansion of human colon-cancer-initiating cells.
###end article-title 75
###begin article-title 76
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential.
###end article-title 76
###begin article-title 77
Increased expression of stem cell markers in malignant melanoma.
###end article-title 77
###begin article-title 78
###xml 60 66 <span type="species:ncbi:10090">murine</span>
Isolation and identification of cancer stem-like cells from murine melanoma cell lines.
###end article-title 78
###begin article-title 79
###xml 26 31 <span type="species:ncbi:9606">human</span>
AC133, a novel marker for human hematopoietic stem and progenitor cells.
###end article-title 79
###begin article-title 80
A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning.
###end article-title 80
###begin article-title 81
CD133: molecule of the moment.
###end article-title 81
###begin article-title 82
CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity.
###end article-title 82
###begin article-title 83
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice.
###end article-title 83
###begin article-title 84
###xml 55 60 <span type="species:ncbi:9606">human</span>
Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells.
###end article-title 84
###begin article-title 85
###xml 65 70 <span type="species:ncbi:9606">human</span>
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.
###end article-title 85
###begin article-title 86
###xml 35 40 <span type="species:ncbi:9606">human</span>
Expression of stem cell markers in human astrocytomas of different WHO grades.
###end article-title 86
###begin article-title 87
Comparative genomics on PROM1 gene encoding stem cell marker CD133.
###end article-title 87
###begin article-title 88
Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.
###end article-title 88
###begin article-title 89
###xml 85 90 <span type="species:ncbi:9606">human</span>
Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer.
###end article-title 89
###begin article-title 90
Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
###end article-title 90
###begin article-title 91
Expression of CD133-1 and CD133-2 in ovarian cancer.
###end article-title 91
###begin article-title 92
In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
###end article-title 92
###begin article-title 93
Dose-dependent inhibition of thyroid differentiation by RAS oncogenes.
###end article-title 93
###begin article-title 94
###xml 113 118 <span type="species:ncbi:9606">human</span>
Characterization of a thyroid hormone-mediated short-loop feedback control of TSH receptor gene in an anaplastic human thyroid cancer cell line.
###end article-title 94
###begin article-title 95
###xml 28 33 <span type="species:ncbi:9606">human</span>
TSH-receptor expression and human thyroid disease: relation to clinical, endocrine, and molecular thyroid parameters.
###end article-title 95
###begin article-title 96
Immunohistochemical detection, regulation and antiproliferative function of G protein-coupled receptor kinase 2 in thyroid carcinomas.
###end article-title 96
###begin article-title 97
Growth suppression of thyroid cancer cells by adenylcyclase activator.
###end article-title 97
###begin article-title 98
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer.
###end article-title 98
###begin article-title 99
###xml 52 57 <span type="species:ncbi:9606">human</span>
CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells.
###end article-title 99
###begin article-title 100
New insights into thyroid stem cells.
###end article-title 100
###begin article-title 101
Thyroid stem cells: lessons from normal development and thyroid cancer.
###end article-title 101
###begin article-title 102
###xml 47 52 <span type="species:ncbi:9606">human</span>
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
###end article-title 102
###begin article-title 103
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors.
###end article-title 103
###begin article-title 104
###xml 62 71 <span type="species:ncbi:10090">nude mice</span>
An orthotopic model of papillary thyroid carcinoma in athymic nude mice.
###end article-title 104
###begin article-title 105
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.
###end article-title 105
###begin article-title 106
###xml 70 75 <span type="species:ncbi:9606">human</span>
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
###end article-title 106
###begin article-title 107
Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53.
###end article-title 107
###begin article-title 108
###xml 46 51 <span type="species:ncbi:9606">human</span>
Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1.
###end article-title 108
###begin p 109
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 109
###begin p 110
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was partly supported by the National Institutes of Health Grant R01 DK068057 (R.Y.L.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 110

